Research on dyslipidaemias in 2017 reaffirmed the central role of reducing the levels of atherogenic apolipoprotein B-containing lipoproteins, predominantly LDL, in preventing ischaemic cardiovascular events. However, whether increasing HDL-cholesterol levels in isolation can reduce cardiovascular risk remains to be determined.
References
Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R. & Tybjaerg-Hansen, A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study. BMJ 357, j1648 (2017).
Sabatine, M. S. et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376, 1713–1722 (2017).
Giugliano, R. P. et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 390, 1962–1971 (2017).
Wang, S. et al. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. Sci. Rep. 7, 39982 (2017).
Vallejo-Vaz, A. J. et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation 136, 1878–1891 (2017).
Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301–1307 (1995).
Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 376, 1430–1440 (2017).
Galabova, G. et al. Peptide-based anti-PCSK9 vaccines — an approach for long-term LDLc management. PLoS ONE 9, e114469 (2014).
Landlinger, C. et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden. CETP mice. Eur. Heart J. 38, 2499–2507 (2017).
Bowman, L. et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med. 377, 1217–1227 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.L.C. received research funding and honoraria as a speaker or consultant for Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Mediolanum, Merck, Pfizer, Recordati, Rottapharm, Sanofi-Regeneron, and Sigma-Tau.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Catapano, A. Atherogenic lipoproteins as treatment targets. Nat Rev Cardiol 15, 75–76 (2018). https://doi.org/10.1038/nrcardio.2017.221
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2017.221
- Springer Nature Limited
This article is cited by
-
High-density lipoproteins may play a crucial role in COVID-19
Virology Journal (2022)
-
Role of cholesterol and sphingolipids in brain development and neurological diseases
Lipids in Health and Disease (2019)